



FORUM
DISCUSSION

Emerging Antimicrobials and Diagnostics in AMR 2019

KIT Royal Tropical Institute Amsterdam
19-20 November 2019

Driving Innovation to combat AMR

Forum Members:

- Kitty van Weezenbeek MD, PhD, MPH; Executive Director KNCV Tuberculosis Foundation (NL)
- Caroline van Oene MD; Associate Director Hospital Acute Care and Immunology MSD (NL)
- Prof Till Bachmann; Deputy Head of Infection Medicine & Personal Chair of Molecular Diagnostics and Infection, Edinburgh Medical School (UK)
- Roy Montijn PhD; Director Microbiology and Systems Biology, TNO (NL)

Driving Innovation to combat AMR

There is a great deal of research and development going on all over the world. At the same time, unfortunately, it has to be said that not enough new products are reaching the market. This is due to a number of factors, including the absence of a solid return-on-investment. But also other factors are debet to this situation.

KNCV Tuberculosis Foundation

(Multi) Resistant Tuberculosis is a great and escalating threat to global health:

- What are the 3 innovations needed to combat (multi)resistant TB?
- What are the bottlenecks to develop and implement these innovations?
- What should be done to overcome these bottlenecks?

Big Pharma is often considered to be the sector that contributes insufficiently to the fight against AMR. This seems mainly because the return on investment is insufficient.

- Is this a justified accusation or is the reality different?
- How does MSD behave in this respect?

As one of the co-authors of the Nature Publication ‘Developmental roadmap for antimicrobial susceptibility testing systems’:

- What is the real role and contribution of antimicrobial susceptibility testing to curbing global AMR?
- What most important innovations are needed? Can these be expected and by when?
- What bottlenecks do you foresee and what should be done to circumvent these?
- Is there a role to play for companion diagnostics?

TNO as an international contract R&D organisation is a partner in a large number of industrial innovations including novel antimicrobials, diagnostics and technology platforms.

- Are your industrial partners sufficiently prepared to invest in innovation and new products?
- What are the industries' hesitations to invest in R&D?
- Could it help if governments take on part of the IP (and then also claim part of the revenues)?